Eli Lilly and Company, the Indianapolis-based drugmaker behind weight-loss drug Mounjaro, diabetes treatments like Trulicity, and cancer therapy Verzenio, is deepening its ties with India.
The company began operations in the country in 1993 as a joint venture with Ranbaxy Laboratories. It now operates in the country with a commercial site in Gurugram and specialised sites in Bengaluru and Hyderabad.
On Monday, Eli Lilly said it would invest $1 billion into India over the next few years. It will set up a new hub in Hyderabad to offer advanced technical capabilities and oversight for Lilly's contract manufacturing network across India.
Lilly’s India link
Eli Lilly and Co said the move aims to tap into India’s skilled workforce and competitive costs, with job openings for engineers, chemists, quality control specialists and managers expected soon.
Patrik Jonsson, Executive Vice President and President, Lilly International, Eli Lilly and Company, praised India’s contract manufacturing networks. He noted that working with local partners helps scale up production “with quality always at the core.”
Since 2020, Eli Lilly has invested over $55 billion worldwide in new plants and upgrades to support treatments for diabetes, obesity, Alzheimer’s, cancer and autoimmune diseases.
Telangana Chief Minister A. Revanth Reddy highlighted the city’s growing stature after Eli Lilly opened its Innovation and Technology site there and launched earlier manufacturing collaborations.
"Telangana secured a massive investment of $1 billion by US Pharma major Eli Lilly, which will expand its manufacturing and global medicine supply capacity in Hyderabad," according to an official statement.
The $1 billion infusion is expected to help Eli Lilly meet rising demand for medicines and strengthen its global supply chain—all while creating thousands of local jobs.
